Firenze

• HeArt Rate and quality of Life in transthyrEtin cardiac amYloidosis (HARLEY) Pending
  2024-519107-10-00 6 transthyretin cardiac amyloidosis
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo … Recruiting
  2025-522093-36-00 10 2026-05-20 Cancer cachexia
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes. Recruiting
  2024-520133-72-00 4 2025-02-05 Myelodysplastic syndromes
• Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting
  2024-519310-31-00 4 2025-01-27 Anemia due to MDS with del5q with IPSS-R very low, low, or intermediat
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a … Recruiting
  2023-504169-22-02 5 2024-07-31 Severe cardiac inflammation
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 9 2022-05-18 Low risk myelodysplastic syndrom without RS having failed or being ine
• Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati … Ended recruitment
  2024-511439-84-00 4 2023-03-30 non-resectable hepatocellular carcinoma (HCC)
• A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended recruitment
  2023-509750-58-00 5 2022-09-21 Polycythemia Vera
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Ended recruitment
  2024-518909-18-00 5 2021-03-23 HIV-1 infected individuals currently taking an INSTI-based three-drug
• IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended recruitment
  2024-517489-41-00 5 2017-03-27 High-risk stage III colon cancer

Showing 1–16 of 16 trials